MedTrace Logo

Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

NCT06250036 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-08-21

No results posted yet for this study

Summary

A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ) adenocarcinoma (AC)

Conditions

  • Locally Advanced Gastric Adenocarcinoma
  • MSI-H/dMMR Gastric Cancer
  • MSI-H/dMMR Gastroesophageal-junction Cancer

Interventions

DRUG

Single agent zimberelimab

Single agent zimberelimab (PD-1 inhibitor) Q3W

DRUG

Combination zimberelimab + domvanalimab

Combination zimberelimab + domvanalimab (TIGIT inhibitor) Q3W

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Royal Marsden NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Naureen Starling · The Royal Marsden NHSFT UK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-20
Primary Completion
2027-03-20
Completion
2031-09-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06250036 on ClinicalTrials.gov